SCH 527123--CXCR2 RECEPTOR ANTAGONIST
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $231,543 | 17 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $231,543 | 17 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase II Study of Navarixin MK-7123 in Combination with Pembrolizumab MK-3475 in Participants with Selected Advanced,Metastatic Solid Tumors | Merck Sharp & Dohme Corporation | $231,543 | 0 |
Top Doctors Receiving Payments for SCH 527123--CXCR2 RECEPTOR ANTAGONIST
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | New York, NY | $231,543 | 17 |
Manufacturing Companies
- Merck Sharp & Dohme Corporation $231,543
Product Information
- Type Drug
- Total Payments $231,543
- Total Doctors 0
- Transactions 17
About SCH 527123--CXCR2 RECEPTOR ANTAGONIST
SCH 527123--CXCR2 RECEPTOR ANTAGONIST is a drug associated with $231,543 in payments to 0 healthcare providers, recorded across 17 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2018 to 2018. In 2018, $231,543 was paid across 17 transactions to 0 doctors.
The most common payment nature for SCH 527123--CXCR2 RECEPTOR ANTAGONIST is "Unspecified" ($231,543, 100.0% of total).
SCH 527123--CXCR2 RECEPTOR ANTAGONIST is associated with 1 research study, including "A Phase II Study of Navarixin MK-7123 in Combination with Pembrolizumab MK-3475 in Participants with Selected Advanced,Metastatic Solid Tumors" ($231,543).